

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Yigong Shi

Serial No.: 09/965,967 Group Art Unit: 1646

Filing Date: September 28, 2001 Examiner: Not yet assigned

For: COMPOSITIONS AND METHODS FOR REGULATING APOPTOSIS

DATE OF DEPOSIT: 4/23/0>
I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO U.S. PATENT AND TRADEMARK OFFICE, BOX SEQUENCE, P.O. BOX 2327, ARLINGTON, VIRGINIA

TYPEO NAME: Janet E. Reed REGISTRATION NO.: 36,252

U. S. Patent and Trademark Office

Box Sequence, P.O. Box 2327 Arlington, Virginia 22202

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

In response to the "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated March 21, 2002, a response to which is due May 21, 2002, enclosed herewith is:

- Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;
- Substitute pages of the Sequence Listing;
- Substitute copy of the computer readable form of amended Sequence Listing;
- Amendment Directing Entry of Sequence Listing into Specification is attached

Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;				
Other:				
Request is hereby made under 37 CFR 1.136(a) to extend the time for respo to the Notice to File Missing Parts of Application of @@ to and through @ comprising an extension of the shortened period of @@ months:				

	SMALL ENTITY		NOT SMALL ENTITY	
	RATE	FEE	RATE	FEE
□ ONE MONTH EXTENSION OF TIME	\$ 55	\$	\$110	\$
☐ TWO MONTH EXTENSION OF TIME	\$200	\$	\$400	\$
☐ THREE MONTH EXTENSION OF TIME	\$460	\$	\$720	s
□ FOUR MONTH EXTENSION OF TIME	\$720	\$	\$1440	\$
☐ FIVE MONTH EXTENSION OF TIME	\$980	\$	\$1960	\$
TOTAL FEE DUE		9		

Applicant(s) has/have not been notified that the requested extension will not be permitted. The present application is not involved in an interference declared pursuant to 37 CFR 1.207.

Total fee required \$@@

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in duplicate.


Date:

Janet E. Reed

Registration No. 36,252

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439





United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.usoto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/965,967

09/28/2001

Yigong Shi

PU-0031

CONFIRMATION NO. 5189

FORMALITIES LETTER

Woodcock Washburn LLP 46th Floor One Liberty Place Philadelphia, PA 19103



Date Mailed: 03/21/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

HE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Yigong Shi

Serial No.: 09/965,967 **Group Art Unit:** 1646

Filing Date: September 28, 2001 Examiner: Not yet assigned

For: COMPOSITIONS AND METHODS FOR REGULATING APOPTOSIS

I, Janet E. Reed, Registration No. 36,252 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Janet E. Reed Reg. No. 36,252

U. S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, Virginia 22202

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
\boxtimes	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

DOCKET NO.: PU-0031

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Date:

Dat

Registration No. 36,252

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2001 WW